1993: 5 of a total of 7 (72%) patients achieved total eradication of their cancer (R/R AML), page-19

It’s a nice graph wombat777 but the devil is in the detail.

The results for Bisantrene are drawn from papers in published journals. These papers have been peer reviewed and enable you to drill down on the results.

For example in the Spadea paper. 5/7 achieved CR with a median time of 45 days. With CR defined as defined as “< 5% blast cells in a normocellular bone marrow with peripheral blood cell count in the normal range.”

Of these 5, three relapsed (at 7, 11, 12 months). Of the 5 only 2 completed the study. One exited with toxicity, one discontinued because of renal failure and one refused further therapy.

The results for PTX-200 are in an ASX announcement.

There is no way of knowing how exactly the company has defined a complete response. The trial registration reporting the efficacy outcome is poorly specified. But let’s assume it is using the standard 5% definition.

Of the 3/15 with CR when did this occur and have they relapsed and over what period of time? Who were they exactly? What treatments did they receive?

No answers.

The complete lack of detail means these efficacy results are unevaluatable. It makes no sense to compare them to the published results. You basically have the company (through the PI) saying they think the results were very encouraging.

It’s a complete so what.

The only “news” in that announcement was that the trial was being halted. The rest was just company puffery.

in one way this all does present a wonderful opportunity for RAC.

Half the reason I think people with on-line share trading accounts invest in life sciences companies is that they have half a brain and want to use it to learn and develop expertise.

Stop treating people like idiots … and you will attract a crowd.

But whether it is viable will be interesting to see. Pump and dumps are integral to how ASX micro-caps are funded … and in order for these you have to create little market misunderstandings … such as CR = complete eradication = cure.

So it’s a funny question … can life-sciences companies be funded without suckers?